These demands were presented at the 2nd Northeastern National Meeting of Cannabis Associations, according to Agencia Brasil.

  Representatives of these organizations highlighted the legal uncertainty that, they claim, still affects their operations, citing recent cases of package seizures and police destruction of crops used as raw materials for medicines.

  Mauricio Gomes, legal director of the Florescer Association, questioned the lack of concrete progress since the approval of Resolution 1,014/2026 by the National Health Surveillance Agency (Anvisa).

  This regulation establishes specific rules for non-profit patient associations, prohibits the commercialization of products, and creates an experimental regulatory framework intended for controlled trials.

  Gomes highlighted the five-year timeframe set for organizations to adapt to the new regulatory landscape and maintained that difficulties persist in determining how they should interact with health and law enforcement authorities.

  Antonio Carlos Araujo, a technical expert from Ceara’s Health Surveillance Coordination—who recognized the existing uncertainty—reported that public participation was ensured during the drafting of the new rules, noting that 29 consultations were held with patient associations and the scientific community, alongside an analysis of international experiences.

jdt/ga/dsa